Evidence map›Paper›PMID 21819438›Full record

ArticleClinical endocrinology2012

Reduced growth hormone secretion in obesity is associated with smaller LDL and HDL particle size.

Hideo Makimura, Meghan N Feldpausch, Takara L Stanley, Noelle Sun, Steven K Grinspoon

Abstract read
In one paragraph

Article in Clinical endocrinology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.The Journal of clinical endocrinology and metabolism · 2014
    Trial
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2015
    Review
  9. Discordance of IGF-1 and GH stimulation testing for altered GH secretion in obesity.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2014
    Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Hideo MakimuraProgram in Nutritional Metabolism and Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. hmakimura@partners.org
Meghan N Feldpausch
Takara L Stanley
Noelle Sun
Steven K Grinspoon
Harvard University · USMassachusetts General Hospital · US

Funding

HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
ZD6416 Analgesic--Painful Distal Symmetrical PolyneuropaM01RR001066 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI BROWN, EMERY N · 1985 to 2008
$37.4M
ROLE OF DIETARY CONSTITUENTS ON GENE EXPRESSION IN INTESTINAL EPITHELIUMP30DK040561 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI CHRISTOPHER P DUGGAN · 1994 to 2026
$31.6M
Consequences and Treatment of Growth Hormone Deficiency in the Metabolic SyndromeR01HL085268 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI GRINSPOON, STEVEN K. · 2007 to 2010
$2.4M
Strategies to Improve CAD Risk In HIV DiseaseK24DK064545 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI GRINSPOON, STEVEN K. · 2003 to 2012
$1.6M
Growth Hormone, Mitochondria, and Cardio-metabolic Complications of ObesityK23DK087857 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI MAKIMURA, HIDEO · 2010 to 2014
$796k
Metabolic Effects of Augmenting Pulsatile Growth Hormone Secretion in HIV-InfectiK23DK089910 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI STANLEY, TAKARA LEAH · 2010 to 2014
$795k
NCRR NIH HHS M01 RR001066NCRR NIH HHS M01RR01066NCRR NIH HHS UL1 RR025758NCRR NIH HHS UL1RR025758NHLBI NIH HHS R01 HL085268NHLBI NIH HHS R01HL085268NIDDK NIH HHS K23 DK087857NIDDK NIH HHS K23DK087857NIDDK NIH HHS K23 DK089910NIDDK NIH HHS K23DK089910NIDDK NIH HHS K24 DK064545NIDDK NIH HHS K24DK064545NIDDK NIH HHS P30 DK040561
6 · The paper itself

Abstract

objectiveReduced growth hormone (GH) secretion is observed in obesity and may contribute to increases in cardiovascular disease (CVD) risk. Lipoprotein characteristics including increased small dense low-density lipoprotein (LDL) particles are known independent risk factors for CVD. We hypothesized that reduced GH secretion in obesity would be associated with a more atherogenic lipid profile including increased small dense LDL particles.

designTo evaluate this hypothesis, we studied 102 normal weight and obese men and women using standard GH stimulation testing to assess GH secretory capacity and performed comprehensive lipoprotein analyses including determination of lipoprotein particle size and subclass concentrations using proton NMR spectroscopy.

resultsObese subjects were stratified into reduced or sufficient GH secretion based on the median peak-stimulated GH (≤6·25 μg/l). Obese subjects with reduced GH secretion (n = 35) demonstrated a smaller mean LDL and HDL particle size in comparison to normal weight subjects (n = 33) or obese subjects with sufficient GH (n = 34) by ANOVA (P < 0·0001). Univariate analyses demonstrated peak-stimulated GH was positively associated with LDL (r = 0·50; P < 0·0001) and HDL (r = 0·57; P < 0·0001), but not VLDL (P = 0·06) particle size. Multivariate regression analysis controlling for age, gender, race, ethnicity, tobacco, use of lipid-lowering medication, BMI and HOMA demonstrated peak-stimulated GH remained significantly associated with LDL particle size (β = 0·01; P = 0·01; R(2) = 0·42; P < 0·0001 for overall model) and HDL particle size (β = 0·008; P = 0·001; R(2) = 0·44; P < 0·0001 for overall model).

conclusionsThese results suggest reduced peak-stimulated GH in obesity is independently associated with a more atherogenic lipoprotein profile defined in terms of particle size.

Indexed as

AdultCardiovascular DiseasesCholesterol Ester Transfer ProteinsFemaleHuman Growth HormoneHumansLipoproteins, HDLLipoproteins, LDLMaleObesityParticle SizeRegression AnalysisCholesterol Ester Transfer ProteinsHuman Growth HormoneLipoproteins, HDLLipoproteins, LDL

Identifiers

PMID21819438
PMCPMC3253195
OpenAlexW1507898828

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.